The Pharma.AI platform
combining deep generative models
(GAN), reinforcement learning (RL), transformers, and
other modern machine learning techniques enables the identification
of novel targets, generation of
novel molecules non-existent
in the chemical space, and prediction of outcomes for clinical
trials.
SAN ANTONIO, Jan. 25, 2022 /PRNewswire/ -- Based on its recent
analysis of the global artificial intelligence (AI)-enabled drug
discovery industry, Frost & Sullivan recognizes Insilico
Medicine with the 2022 Entrepreneurial Company of the Year Award in
the global AI-enabled drug discovery industry.
Pharma.AI, the end-to-end AI-enabled drug discovery and
development platform of Insilico, addresses challenges that touch
on chemistry, biology, and digital medicine. The combined AI and
drug discovery expertise enable the identification of novel
targets, generation of novel molecules non-existent in the chemical
space, and prediction of outcomes for clinical trials. The AI
solutions and verified automated AI platform streamline research
and development (R&D) efforts, remodel therapeutics discovery,
and advance precision medicine. In addition, these solutions
accelerate research workflow, leading to rapid and cost-effective
discovery and development.
According to Supriya Lala Kundu,
industry analyst at Frost & Sullivan, "Insilico's AI platforms
integrate GANs, reinforcement learning (RL), and transformer neural
networks to automate multi-targeting, polypharmacolocogy, and
holistic diseases assessment. The company is working on AI-powered
robotics to create driverless drug discovery as it moves towards
advanced technologies and 100% automation."
PandaOmics is one of the
AI-enabled engines of Pharma.AI
which integrates proteomics, transcriptomics, and other
data types with advanced AI algorithms. PandaOmics supports target
disease identification and supports research and target
identification for different diseases. The AI-powered platform
provides complex algorithms that recommend relevant novel drug
target hypotheses in a few days rather than several months,
significantly reducing drug discovery timelines.
Insilico Medicine also utilizes multiple algorithms that
rapidly evaluate the targets for possible binding sites to address
the challenge of transitioning from target to small molecules with
desired properties. Chemistry42, a small molecule generation engine
of Pharma.AI platform with 30 algorithms, identifies the right
pockets and designs a range of molecules that do not exist in the
chemical space within a few days. In addition, the engine enables
the filtering from billions of generated molecules to identify
easy-to-synthesize and inexpensive-to-develop molecules with the
highest success potential. Chemistry42TM , a cloud and
on-premise hardware-agnostic and scalable platform that can be
licensed and tested by clients, delivers new actionable drug-like
molecules in days.
"Insilico leverages its proprietary AI-driven platforms to
effectively address the challenges of identifying accurate targets,
developing novel molecular structures with desired parameters, and
predicting clinical trial outcomes. Its deep technical expertise
facilitates accelerated and cost-efficient novel therapeutic
compound design and innovative drug discovery for cancer, fibrosis,
infectious diseases, and aging-related diseases. For example, in
2021, Insilico initiated the first-in-human study of a potentially
first-in-class drug candidate with a novel target
for fibrosis. Notably, the company completed the entire
discovery process from target discovery to preclinical candidate
nomination within 18 months on a budget of $2.6 million. Furthermore, Insilico nominated two
preclinical candidates with a novel molecular structure for anemia
of chronic kidney disease and inflammatory bowel disease within 12
months using its AI engine. Such milestones thoroughly validate
Insilico's AI platform as robust and effective," Kundu explained
further.
In addition to the two engine mentioned above that have already
been launched as software, InClinicoTM , another
AI-powered engine in development by Insilico which could
provide prediction of outcomes for clinical trials
has exciting prospects as well. With its strong overall
performance, growing partnerships, focus on innovation, and
expertise in end-to-end drug discovery and development, Insilico
Medicine earns Frost & Sullivan's 2022 Entrepreneurial Company
of the Year Award in the global AI-enabled drug discovery
industry.
Each year, Frost & Sullivan presents this award to the
company that has demonstrated excellence in devising and
implementing a strong growth strategy. The recipient has shown
strength in terms of innovation in products and technologies,
leadership in customer value, and speed in response to market
needs. The award looks at the emerging market participants in the
industry and recognizes their best practices that are positioned
for future growth excellence.
Frost & Sullivan Best Practices Awards recognize companies
in various regional and global markets for demonstrating
outstanding achievement and superior performance in leadership,
technological innovation, customer service, and strategic product
development. Industry analysts compare market participants and
measure performance through in-depth interviews, analyses, and
extensive secondary research to identify best practices in the
industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned
for its role in helping investors, corporate leaders, and
governments navigate economic changes and identify disruptive
technologies, Mega Trends, new business models, and companies to
action, resulting in a continuous flow of growth opportunities to
drive future success. Contact us: Start the discussion.
Contact:
Kala Mani. S.
Phone: +603-2023 2037
Email: kala.manis@frost.com
About Insilico Medicine
Insilico Medicine, an end-to-end AI-driven drug discovery and
development company, is connecting biology, chemistry, and clinical
trials analysis using next-generation AI systems. Insilico Medicine
has developed AI platforms that utilize deep generative models,
reinforcement learning, transformers, and other modern machine
learning techniques to discover novel targets and to design novel
molecular structures with desired properties. Insilico Medicine is
delivering breakthrough solutions to discover and develop
innovative drugs for cancer, fibrosis, immunity, central nervous
system (CNS) diseases and aging-related diseases. For more
information, visit www.insilico.com.
Photo -
https://mma.prnewswire.com/media/1733139/Insilico_Medicine_Frost_Sullivan_Award.jpg